Nalaganje...
Rapid disease progression after discontinuation of lenvatinib in thyroid cancer
Some thyroid cancer patients experience a rapid disease progression after the discontinuation of tyrosine kinase inhibitors (TKIs), which is called flare phenomenon. The incidence of the flare phenomenon of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) ranged from 4% to 11....
Shranjeno v:
| izdano v: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Wolters Kluwer Health
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7220477/ https://ncbi.nlm.nih.gov/pubmed/32176066 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000019408 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|